

AMENDMENTS TO THE CLAIMS

1. (Currently Amended) ~~An~~ A method for improving insulin resistance ~~improving in a~~
subject in need thereof comprising administering an effective amount of an agent containing,
as an active component, a C-terminal globular domain of adiponectin, adiponectin, or a gene
for the domain or adiponectin.

2. (Withdrawn) An insulin resistance improving agent containing, as active
components, a C-terminal globular domain of adiponectin, adiponectin, or a gene for the
domain or adiponectin, and leptin or a gene for leptin.

3. (Currently Amended) A method for treating type 2 diabetes in a subject in need
thereof comprising administering an effective amount of a therapeutic agent for type 2
diabetes containing, as an active component, a C-terminal globular domain of adiponectin,
adiponectin, or a gene for the domain or adiponectin.

4. (Withdrawn) A therapeutic agent for type 2 diabetes containing, as active
components, a C-terminal globular domain of adiponectin, adiponectin, or a gene for the
domain or adiponectin, and leptin or a gene for leptin.

5. (New) The method of claim 1, wherein said agent further comprises a
pharmacologically acceptable carrier.

6. (New) The method of claim 5, wherein said pharmacologically acceptable carrier is

selected from the group consisting of distilled water, a solubilizer, a stabilizer, an emulsifier, and a buffer.

7. (New) The method of claim 1, wherein said administering is by injection.

8. (New) The method of claim 1, wherein said effective amount ranges from 0.1 µg/day to 10 mg/day based on the amount of adiponectin.

9. (New) The method of claim 3, wherein said therapeutic agent further comprises a pharmacologically acceptable carrier.

10. (New) The method of claim 9, wherein said pharmacologically acceptable carrier is selected from the group consisting of distilled water, a solubilizer, a stabilizer, an emulsifier, and a buffer.

11. (New) The method of claim 3, wherein said administering is by injection.

12. (New) The method of claim 3, wherein said effective amount ranges from 0.1 µg/day to 10 mg/day based on the amount of adiponectin.

SUPPORT FOR THE AMENDMENTS

Claims 1 and 3 have been amended.

Claims 5-12 have been added.

The amendment of Claims 1 and 3, as well as the introduction of new Claims 5-12, is supported by the specification at, for example, page 3, lines 2-6, page 6, line 17 to page 7, line 18, and the Examples.

No new matter has been entered by the present amendment.